Tag
Combining serum leucine-rich alpha-2-glycoprotein 1 (LRG-1) with citrulline offers a sensitive, noninvasive biomarker strategy for early detection and monitoring of rejection in intestinal transplantation, potentially reducing reliance on i
This study reveals sustained elevations in inflammatory and cartilage metabolism serum biomarkers during the first year after ACL reconstruction, indicating ongoing joint biological responses beyond surgery and rehabilitation.
Elevated baseline CRP levels in older acute HF patients identify those who gain the most physical function improvement from a 12-week rehabilitation program, supporting biomarker-guided therapy.
Early increases in serum ST2 and REG3α within the first week after haploidentical stem cell transplantation with post-transplant cyclophosphamide predict transplant outcomes, highlighting their potential as prognostic biomarkers.
A multicenter study demonstrates that interpretable machine learning applied to baseline OCT biomarkers accurately predicts chronicity in central serous chorioretinopathy, facilitating early risk stratification and personalized management.
This study reveals that lower serum GLP-1 levels are independently associated with endometrial cancer in obese, non-diabetic women, suggesting its potential as a diagnostic biomarker with high sensitivity and specificity.
HEARTBiT, a novel transcriptomic biomarker, effectively detects moderate-to-severe acute cellular rejection within the first year after heart transplantation, offering a minimally invasive alternative to biopsy, especially during the high-r
Peritoneal fluid-derived small extracellular vesicles exhibit distinct proteomic profiles in endometriosis, identifying potential biomarkers for improved diagnosis independent of cycle phase or disease stage.
This study reveals significantly reduced ACE protein levels in cerebrospinal fluid and serum of early-stage psychosis patients, particularly in treatment-resistant cases, highlighting a potential biomarker and mechanistic role beyond enzyma
This study introduces a standardized 5-class framework for tau PET imaging to better detect and stage Alzheimer’s disease, improving early diagnosis and patient stratification across different tracers.
This article reviews over 1100 studies on novel biomarkers for acute kidney injury (AKI) in critically ill patients, highlighting their predictive, diagnostic, and management roles while identifying gaps for future clinical implementation.
Host blood transcriptomic signatures effectively monitor treatment response and predict recurrence and mortality in drug-susceptible pulmonary tuberculosis, meeting WHO benchmarks and enabling personalized therapy strategies.
Large-scale proteomic analysis identifies novel maternal plasma protein biomarkers that improve detection of fetal death beyond established markers, highlighting both shared and unique pathological pathways with preeclampsia.
Comprehensive proteomic and phosphoproteomic profiling of 267 neuroendocrine carcinomas across multiple tissues reveals distinct molecular subtypes, biomarkers, and a novel NAD+ metabolic vulnerability, advancing personalized precision medi
Elevated plasma pro-opiomelanocortin (POMC) levels accurately predict silent corticotroph adenomas (SCAs) among clinically non-functioning pituitary adenomas, offering a promising tool for diagnosis and monitoring.
Serum neurofilament light chain (sNfL) z-score dynamics enhance monitoring of treatment response in relapsing multiple sclerosis (RMS), providing complementary predictive value for disease activity beyond conventional clinical and MRI asses
A multiprotein plasma panel improves detection of advanced neocortical tau pathology in Alzheimer’s disease risk individuals beyond p-tau217 alone, enhancing patient stratification and clinical trial selection.
The ENIGMA study reveals altered metabolism of the emulsifier polysorbate-80 and elevated artificial sweeteners in Crohn’s disease, linking these dietary additives to disease activity and potential biomarker development.
Serum GFAP elevation predicts progression independent of relapse in MS; therapy-induced GFAP reduction associates with decreased progression risk, supporting GFAP as a biomarker for progression risk stratification and treatment monitoring.
An expert consensus (STARDaki) extends STARD to improve reporting of diagnostic test accuracy studies for acute kidney injury (AKI), specifying patient selection, reference standards, timing, assay details and test-retest reliability.
